Literature DB >> 27137648

Combined gadoxetic acid and gadofosveset enhanced liver MRI for detection and characterization of liver metastases.

Peter Bannas1,2, Candice A Bookwalter3, Tim Ziemlewicz3, Utaroh Motosugi3,4, Alejandro Munoz Del Rio3, Theodora A Potretzke3, Scott K Nagle3,5,6, Scott B Reeder3,5,7,8,9.   

Abstract

PURPOSE: To compare gadoxetic acid alone and combined gadoxetic acid/gadofosveset trisodium-enhanced liver MRI for detection of metastases and differentiation of metastases from haemangiomas.
METHODS: Ninety-one patients underwent gadoxetic acid-enhanced liver MRI before and after additional injection of gadofosveset. First, two readers retrospectively identified metastases on gadoxetic acid alone enhanced delayed hepatobiliary phase T1-weighted images together with all other MR images (dynamic images, T2-weighted images, diffusion-weighted images). Second, readers assessed additional T1-weighted images obtained after administration of gadofosveset trisodium. For both interpretations, readers rated lesion conspicuity and confidence in differentiating metastases from haemangiomas. Results were compared using alternative free-response receiver-operating characteristic (AFROC) and conventional ROC methods. Histology and follow-up served as reference standard.
RESULTS: There were 145 metastases and 16 haemangiomas. Both readers detected more metastases using combined gadoxetic acid/gadofosveset (reader 1 = 130; reader 2 = 124) compared to gadoxetic acid alone (reader 1 = 104; reader 2 = 103). Sensitivity of combined gadoxetic acid/gadofosveset (reader 1 = 90 %; reader 2 = 86 %) was higher than that of gadoxetic acid alone (reader 1 = 72 %; reader 2 = 71 %, both P < 0.01). AFROC-AUC was higher for the combined technique (0.92 vs. 0.86, P < 0.001). Sensitivity for correct differentiation of metastases from haemangiomas was higher for the combined technique (reader 1 = 98 %; reader 2 = 99 % vs. reader 1 = 86 %; reader 2 = 91 %, both P < 0.01). ROC-AUC was significantly higher for the combined technique (reader 1 = 1.00; reader 2 = 1.00 vs. reader 1 = 0.87; reader 2 = 0.92, both P < 0.01).
CONCLUSION: Combined gadoxetic acid/gadofosveset-enhanced MRI improves detection and characterization of liver metastases compared to gadoxetic acid alone. KEY POINTS: • Combined gadoxetic acid and gadofosveset-enhanced liver MRI significantly improves detection of metastases. • The combined enhancement technique improves the accuracy to differentiate metastases from haemangiomas. • Prospective studies need to determine the clinical impact of the combined technique.

Entities:  

Keywords:  Gadofosveset trisodium; Gadoxetic acid; Liver; Magnetic resonance imaging; Metastases

Mesh:

Substances:

Year:  2016        PMID: 27137648      PMCID: PMC5562159          DOI: 10.1007/s00330-016-4375-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  33 in total

1.  Observer studies involving detection and localization: modeling, analysis, and validation.

Authors:  Dev P Chakraborty; Kevin S Berbaum
Journal:  Med Phys       Date:  2004-08       Impact factor: 4.071

2.  Hepatic cavernous hemangioma: appearance on T2-weighted fast spin-echo MR imaging with and without fat suppression.

Authors:  P Soyer; A C Dufresne; E Somveille; A Scherrer
Journal:  AJR Am J Roentgenol       Date:  1997-02       Impact factor: 3.959

3.  Hepatic lesion detection: comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using alternative-free response receiver operating characteristic analysis.

Authors:  J Ward; K S Naik; J A Guthrie; D Wilson; P J Robinson
Journal:  Radiology       Date:  1999-02       Impact factor: 11.105

4.  Imaging of atypical hemangiomas of the liver with pathologic correlation.

Authors:  V Vilgrain; L Boulos; M P Vullierme; A Denys; B Terris; Y Menu
Journal:  Radiographics       Date:  2000 Mar-Apr       Impact factor: 5.333

5.  "Pseudo washout" sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor.

Authors:  Kyung Won Doo; Chang Hee Lee; Jae Woong Choi; Jongmee Lee; Kyeong Ah Kim; Cheol Min Park
Journal:  AJR Am J Roentgenol       Date:  2009-12       Impact factor: 3.959

6.  Computed tomography of cavernous hemangioma of the liver.

Authors:  Y Itai; S Furui; T Araki; N Yashiro; A Tasaka
Journal:  Radiology       Date:  1980-10       Impact factor: 11.105

7.  Differential diagnosis between metastatic tumors and nonsolid benign lesions of the liver using ferucarbotran-enhanced MR imaging.

Authors:  Hiroki Higashihara; Takamichi Murakami; Tonsok Kim; Masatoshi Hori; Hiromitsu Onishi; Saki Nakata; Keigo Osuga; Kaname Tomoda; Hironobu Nakamura
Journal:  Eur J Radiol       Date:  2008-11-18       Impact factor: 3.528

Review 8.  Colorectal liver metastases: state of the art imaging.

Authors:  Kathryn Jane Fowler; David C Linehan; Christine O Menias
Journal:  Ann Surg Oncol       Date:  2012-11-01       Impact factor: 5.344

9.  Incremental value of liver MR imaging in patients with potentially curable colorectal hepatic metastasis detected at CT: a prospective comparison of diffusion-weighted imaging, gadoxetic acid-enhanced MR imaging, and a combination of both MR techniques.

Authors:  Hye Jin Kim; Seung Soo Lee; Jae Ho Byun; Jin Cheon Kim; Chang Sik Yu; Seong Ho Park; Ah Young Kim; Hyun Kwon Ha
Journal:  Radiology       Date:  2014-10-03       Impact factor: 11.105

10.  Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases.

Authors:  C J Zech; P Korpraphong; A Huppertz; T Denecke; M J Kim; W Tanomkiat; E Jonas; A Ba-Ssalamah
Journal:  Br J Surg       Date:  2014-03-20       Impact factor: 6.939

View more
  4 in total

Review 1.  [Optimized detection and characterization of liver metastases : The role of current MRI contrast agents].

Authors:  J M Weinrich; L Well; P Bannas
Journal:  Radiologe       Date:  2017-05       Impact factor: 0.635

Review 2.  Deciphering albumin-directed drug delivery by imaging.

Authors:  Huiyu Hu; Jeremy Quintana; Ralph Weissleder; Sareh Parangi; Miles Miller
Journal:  Adv Drug Deliv Rev       Date:  2022-03-29       Impact factor: 17.873

3.  Non-contrast MR angiography at 1.5 Tesla for aortic monitoring in Marfan patients after aortic root surgery.

Authors:  Simon Veldhoen; Cyrus Behzadi; Alexander Lenz; Frank Oliver Henes; Meike Rybczynski; Yskert von Kodolitsch; Thorsten Alexander Bley; Gerhard Adam; Peter Bannas
Journal:  J Cardiovasc Magn Reson       Date:  2017-10-30       Impact factor: 5.364

4.  Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy.

Authors:  Thomas S C Ng; Huiyu Hu; Stefan Kronister; Chanseo Lee; Ran Li; Luca Gerosa; Sylwia A Stopka; Danielle M Burgenske; Ishaan Khurana; Michael S Regan; Sreeram Vallabhaneni; Niharika Putta; Ella Scott; Dylan Matvey; Anita Giobbie-Hurder; Rainer H Kohler; Jann N Sarkaria; Sareh Parangi; Peter K Sorger; Nathalie Y R Agar; Heather A Jacene; Ryan J Sullivan; Elizabeth Buchbinder; Hannes Mikula; Ralph Weissleder; Miles A Miller
Journal:  Sci Adv       Date:  2022-04-29       Impact factor: 14.957

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.